Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2017-08-03 Regulatory Filings
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 90% confidence The document is a Form 8-K filing dated August 3, 2017, from Xenon Pharmaceuticals Inc. It announces the company's financial results for the six-month period ended June 30, 2017, via a press release attached as Exhibit 99.1. The text explicitly states that the information and the press release are furnished to, but not filed with, the SEC. The document itself does not contain detailed financial statements or substantive financial data but rather serves as an announcement of the earnings release. The length of the document is 3346 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER) announcement within an 8-K filing, but since it is the 8-K form announcing the earnings release and not the earnings release itself, and given the short length and nature of the content, the best fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous SEC filings that do not fit other categories.
2017-08-03 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-06-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-06-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text indicates it is reporting "Other Events" related to a clinical trial result announcement and a conference call. It includes a press release as an exhibit and details about the call. The document length is 3660 characters, which is relatively short and primarily serves as an announcement rather than a full report. There are no financial statements or detailed financial data included. The content is consistent with a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Management Reports. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-06-27 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-06-24 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-06-20 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.